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Defective Initiation of Glycosaminoglycan Synthesis
due to B3GALT6 Mutations Causes a Pleiotropic
Ehlers-Danlos-Syndrome-like Connective Tissue Disorder
Fransiska Malfait,1,7,* Ariana Kariminejad,2,7 Tim Van Damme,1 Caroline Gauche,3 Delfien Syx,1
Faten Merhi-Soussi,3 Sandrine Gulberti,3 Sofie Symoens,1 Suzanne Vanhauwaert,1 Andy Willaert,1
Bita Bozorgmehr,2 Mohamad Hasan Kariminejad,2 Nazanin Ebrahimiadib,4 Ingrid Hausser,5
Ann Huysseune,6 Sylvie Fournel-Gigleux,3 and Anne De Paepe1
Proteoglycans are important components of cell plasma membranes and extracellular matrices of connective tissues. They consist of
glycosaminoglycan chains attached to a core protein via a tetrasaccharide linkage, whereby the addition of the third residue is catalyzed
by galactosyltransferase II (b3GalT6), encoded by B3GALT6. Homozygosity mapping and candidate gene sequence analysis in three
independent families, presenting a severe autosomal-recessive connective tissue disorder characterized by skin fragility, delayed wound
healing, joint hyperlaxity and contractures, muscle hypotonia, intellectual disability, and a spondyloepimetaphyseal dysplasia with
bone fragility and severe kyphoscoliosis, identified biallelic B3GALT6 mutations, including homozygous missense mutations in family
1 (c.619G>C [p.Asp207His]) and family 3 (c.649G>A [p.Gly217Ser]) and compound heterozygous mutations in family 2 (c.323_344del
[p.Ala108Glyfs*163], c.619G>C [p.Asp207His]). The phenotype overlaps with several recessive Ehlers-Danlos variants and spondyloe-
pimetaphyseal dysplasia with joint hyperlaxity. Affected individuals’ fibroblasts exhibited a large decrease in ability to prime glycosami-
noglycan synthesis together with impaired glycanation of the small chondroitin/dermatan sulfate proteoglycan decorin, confirming
b3GalT6 loss of function. Dermal electron microcopy disclosed abnormalities in collagen fibril organization, in line with the important
regulatory role of decorin in this process. A strong reduction in heparan sulfate level was also observed, indicating that b3GalT6 defi-
ciency alters synthesis of bothmain types of glycosaminoglycans. In vitro wound healing assay revealed a significant delay in fibroblasts
from two index individuals, pointing to a role for glycosaminoglycan defect in impaired wound repair in vivo. Our study emphasizes a
crucial role for b3GalT6 in multiple major developmental and pathophysiological processes.Proteoglycans (PGs) rank among the most abundant and
structurally complex biomacromolecules. They are found
on the surface of all animal cells and are major compo-
nents of extracellular matrices (ECM), in particular
basement membranes. They are involved in many vital
functions including cell-cell and cell-matrix interactions,
cell proliferation and migration, cytokine and growth fac-
tor signaling, and embryonic and postnatal development
and are implicated in several pathological processes such
as viral infection.1–4 PGs consist of a variable number of
glycosaminoglycan (GAG) side chains attached to a core
protein. GAG chains exhibit considerable structural diver-
sity resulting from a complex biosynthetic pathway, a pro-
cess that is tightly regulated in biological systems, enabling
the modified polysaccharide to selectively interact with a
variety of ligands in a spatially and temporally controlled
manner.5 The structure of the core protein and the compo-
sition of the GAG chains give rise to a great variety of PGs.
GAGs are linear polysaccharides, composed of a repeated
disaccharide unit consisting of an amino sugar (N-acetyl-
glucosamine [GlcNAc] or N-acetylgalactosamine [GalNAc])
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groups depending on the composition of the disaccharide
building block consisting of (GalNAc-GlcA)n or (GlcNAc-
GlcA)n to form chondroitin sulfate (CS)/dermatan sulfate
(DS) PGs (e.g., decorin, biglycan, and thrombomodulin)
and heparan sulfate (HS) PGs (e.g., perlecan, syndecan,
and glypican), respectively. Tightly controlled modifica-
tions, such as epimerization and sulfation, further increase
the structural and functional diversity of GAGs.6,7
The synthesis of GAG chains is initiated by the forma-
tion of a tetrasaccharide linker region attached to a serine
residue of the PG core protein. This so-called linkage region
is indispensable prior to the polymerization of either HS or
CS/DS chains, and its synthesis consists of a stepwise pro-
cess that involves the coordinated action of specific glyco-
syltransferases (see Figure 1 for details). Synthesis of the
linkage region starts by the transfer of xylose onto a serine
residue of the core protein catalyzed by xylosyltransferases
I/II (encoded by XYLT1 [MIM 608124] and XYLT2 [MIM
608125]).8 Subsequently, two galactose residues are added
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Figure 1. Schematic Illustration of
Glycosaminoglycan Synthesis
After synthesis in the endoplasmic reticu-
lum (ER), the core protein is transported
to the Golgi apparatus and simultaneously
undergoes further modifications. First, a
tetrasaccharide linker region is synthesized
that originates from the addition of a
xylose (Xyl) unit onto a serine residue of
the core protein. Subsequent addition of
two galactose (Gal) and one glucuronic
acid (GlcA) residues completes this pro-
cess. Depending on the glycosamino-
glycan (GAG) chain type, disacharide
units consisting of (N-acetylgalactosamine
(GalNAc)-GlcA)n or (N-acetylglucosamine
(GlcNAc)-GlcA)n are polymerized to form
chondroitin sulfate (CS)/dermatan sulfate
(DS)-PGs and heparan sulfate (HS)-PGs,
respectively. The GAG chain is then
further modified by epimerization and
sulfation. Genes and the encoded enzymes
are indicated in the figure. Disorders result-
ing from deficiency of the enzymes are
indicated in black boxes. The deficient
enzyme (b3GalT6) and the related disorder
described in the text are depicted in red.encoded by B3GALT6),11 followed by the transfer of GlcA
catalyzed by glucuronosyltransferase I (GlcAT-I, encoded
by B3GAT3 [MIM 606374])12 to complete the formation
of the tetrasaccharide linkage.
The importance of the correct synthesis of GAGs is
exemplified by the identification of mutations in genes
encoding key enzymes of this synthetic pathway, leading
to severe multisystemic disorders in humans. Loss-of-func-
tion mutations in B4GALT7 have been identified in the
progeroid form of Ehlers-Danlos syndrome (EDS) (MIM
130070),13,14 whereas mutations in B3GAT3 give rise to a
Larsen-like syndrome with joint laxity and cardiac defects
(MIM 245600).15 Further down the biosynthetic pathway,
mutations in genes involved in the processing of CS, such
as CHST3 (MIM 603799) and CHSY1 (MIM 608183), are
associated with spondyloepiphyseal dysplasia Omani-
type (MIM 143095) and recessive Larsen syndrome (MIM
143095)16 and with Temtamy preaxial brachydactyly
syndrome (MIM 605282), respectively.17 Mutations in
CHST14 (MIM 608429) are associated with musculocon-
tractural EDS (MIM 601776)18,19 and adducted-thumb-
clubfoot syndrome (MIM 601776).20 Defects in HS
synthesis (EXT1 [MIM 608177] and EXT2 [MIM 608210])
are linked with hereditary multiple exostoses type I
(MIM 133700) and type II (MIM 133701).21
Here, we report the identification of mutations in
B3GALT6, the gene coding for galactosyltransferase II936 The American Journal of Human Genetics 92, 935–945, June 6, 2013(b3GalT6), in a series of individuals
presenting a severe multisystemic dis-
order, characterized by a unique com-
bination of severe soft connective
tissue and bone fragility withmultipleearly-onset fractures, spondyloepimetaphyseal abnormal-
ities, and intellectual disability. We provide compelling
evidence that loss of function of b3GalT6 causes a severe
deficiency in GAG synthesis and results in the production
of immature decorin, lacking its CS/DS side chain, as well
as reduced-to-absent HS chains in dermal fibroblasts of
affected individuals. We show that the abnormal PG pro-
duction perturbs collagen fibril organization and contrib-
utes to delayed wound closure.
This study was approved by the Ethics Committee of the
Ghent University Hospital (Ghent, Belgium). All affected
family members or their legal guardian provided written
informed consent.
The index individual P1 (Figures 2A–2D), a 7-year-old
child of consanguineous Iranian parents, was born by
caesarian section because of breech presentation at
40 weeks of gestation. Birth length, weight, and occipito-
frontal circumference (OFC) were 49 cm (50th centile),
3,300 g (50th centile), and 36 cm (36th centile), respec-
tively. She presented with congenital muscle hypotonia
and showed mild delay in motor and cognitive develop-
ment. She was able to hold her head at 4 months and sit
at 9 months, said her first words at 18 months, and walked
independently at 2 years. Examination at age 7 years re-
vealed a height of 116 cm (50th centile), weight of 18 kg
(25th centile), and OFC of 51 cm (50th centile). Facial char-
acteristics included blue sclerae, downslanting palpebral
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Figure 2. Clinical and Radiological Characteristics
(A–D) P1 at age 7 years, illustrating (A) a hypotonic appearance, bruises on the lower limbs, and broad, flat feet; (B) skin hyperextensi-
bility; and marked hyperlaxity of the finger joints (D) and broad distal phalanges (C).
(E–H) P2 at age 26 years, illustrating (E) disproportionate short stature with short trunk, severe kyphoscoliosis and pectus deformity, and
an elongated face with prominent chin; (F) thin and hyperextensible skin; (G) slender, tapered fingers with broad distal phalanges and
finger contractures; and (H) broad, flat, and deformed feet and severe hallux valgus.
(I–L) P3 at age 9 years, illustrating (I) severe hypotonia and low muscle mass, short trunk with pectus deformity and kyphoscoliosis,
severely deformed lower limbs with contractures and club feet, and mild facial dysmorphism with low-set ears and prognathism;
(J) small, yellowish teeth; (K, L) excessive wrinkling of the palms of hand and feet; and (K) spatulate fingers with broad distal phalanges.
(M–P) P5 at age 20 months, illustrating (M) generalized hypotonia, low muscle mass, and pectus deformity; (M, N) a mild progeroid
aspect of the face with shallow orbits, blue sclerae, proptosis, short nose, hypoplastic alae nasi, low nasal bridge, sparse hair, and bitem-
poral narrowing; (O) increased palmar wrinkling and broad distal phalanges; and (P) severe foot deformities.
(Q–T) Radiographs of P2 at age 27 years, illustrating (Q) severe kyphosis, osteoporotic, wedged thoracic vertebral bodies; (R) severe prog-
nathism; (S) flared iliac wings with increased trabecular patterning, coxa valga, and mild degenerative acetabular changes; and
(T) osteoporosis of the femur and tibia with increased trabecular patterning.
(U–X) Radiographs of P5 at age 2 years 3 months, illustrating (U) hypoplastic iliac bodies and poorly formed acetabulae;
(U, V) osteoporotic aspect of the femur and tibia, diaphyseal narrowing, broadened metaphyses with abnormal trabecular patterning
and epiphyseal changes; (W) severe kyphoscoliosis with ovoid vertebrae; and (X) mild bowing of humerus, radius, and ulna.fissures, low-set ears, thin lips, and early decay of the teeth.
She presented a thin, hyperextensible, and transparent
skin with visible veins over the thorax. In addition, her
skin was fragile, with easy bruising, splitting upon minor
trauma, difficult wound closure, and slow wound healing.
She presented generalized joint hypermobility and broad,
flat feet and had repetitive shoulder dislocations. She had
no history of fractures, but bone densitometry performed
at age 4 years showed low bone mineral density (BMD)
of the spine (L1–L4), with DEXA Z score of 2.5 SD. She
was treated with intramuscular injection of pamidronate
every 3–4 months for 2 years and is currently on oral
alendronate. This treatment improved her BMD, as shownThe Amby a DEXA Z score of L1–L4 of 0.2 SD at age 7 years. She
goes to school but is slow in learning. She has mild myopia
but no hearing deficit nor cardiac or other internal prob-
lems. Pedigree analysis revealed that she has a maternal
cousin, individual P2 (Figures 2E–2H), who displayed
similar symptoms. This 26-year-old man was born at
40 weeks of gestation after a normal pregnancy and vaginal
delivery. Parents were reported unrelated but are from the
same geographic region in central Iran. Congenital muscle
hypotonia caused delayed gross motor development and
inability to sit and walk independently until ages 2 and
7 years, respectively. He has a history of more than 15
atraumatic fractures of the hands and long bones (tibia,erican Journal of Human Genetics 92, 935–945, June 6, 2013 937
fibula, ulna, and radius) from the age of 7 years. He pre-
sented severe generalized joint hyperlaxity in childhood,
but progressively developed joint contractures, especially
of the finger joints. Kyphoscoliosis was noticed at 7 years
of age and progressed over the years. At age 26 years, his
height, weight, and head circumference were 146 cm
(<3rd centile), 42 kg (<3rd centile), and 51 cm (<3rd cen-
tile), respectively. He presented an elongated face with
prominent chin, blue sclerae, downslanting palpebral fis-
sures, and small teeth. He had loose, thin, and hyperexten-
sible skin, with splitting upon minor trauma, slow wound
healing, atrophic scar formation, and easy bruising. He
showed severe kyphoscoliosis, slender fingers with joint
contractures and broad distal phalanges, and severe foot
deformities with pes planus and hallux valgus. He has
mild myopia and mild intellectual disability. Radiographic
observations at age 27 years are shown in Figures 2Q–2T.
Both individuals were initially suspected to have EDS
VIA (EDS kyphoscoliotic type [MIM 225400]), but the uri-
nary lysylpyridinoline/hydroxylysylpyridinoline (LP/HP)
ratio was within normal range, excluding this diagnosis
(courtesy of Dr. C. Giunta, University Children’s Hospital
and Children’s Research Center, Zurich). Musculocontrac-
tural EDS (EDS type VIB) was excluded by means of
molecular analysis of CHST14. The parents of P1 were
consanguineous, so autosomal-recessive inheritance was
assumed and homozygosity mapping was performed in or-
der to identify candidate genes. Both affected persons and
seven unaffected family members (Figure 3A) were geno-
typed with the 200K genome-wide HumanCytoSNP-12
BeadChip SNP array (Illumina). Homozygosity mapping
was performed with the web-based HomozygosityMapper
application with the recommended default settings, and
the results were validated through pairwise genotype clus-
tering with PLINK (v.1.07, default settings).22,23 This anal-
ysis revealed a ~1 Mb homozygous region on chromosome
1 (dbSNP rs3094315 till rs6681938) harboring 63 genes of
which 44 encode known or predicted proteins (Figure S1
available online). The coding sequence and 50 and 30
untranslated regions (UTRs) of B3GALT6, a positional
and functional candidate gene, were PCR amplified via
gDNA samples from individuals P1 and P2. Amplicons
were subsequently analyzed on an ABI 3730XL DNA
Analyzer (Life Technologies) with the BigDye Terminator
Cycle Sequencing kit (Life Technologies). Comparison
with the B3GALT6 reference sequence (RefSeq accession
number NM_080605.3) with the SeqScape Software pack-
age (Life Technologies, v.2.5) identified a homozygous
missense variant c.619G>C (p.Asp207His) in P1 and P2.
The Asp207 amino acid residue (Figure 3B) is highly
conserved among species (Figure 3C), and its substitution
is predicted to have deleterious effects on protein function
(Table S2).
We subsequently studied three additional individuals
from two independent families with a similar clinical
phenotype. Individual P3 (Figures 2I–2L) is a 9-year-old
boy and first child of a nonconsanguineous couple of938 The American Journal of Human Genetics 92, 935–945, June 6, 2Iranian origin. The mother is from the same geographic
region in central Iran as family 1. He was born at 39 weeks
of gestation after an uneventful pregnancy by elective
caesarian section with a birth length of 50 cm (50th cen-
tile), birth weight of 3,350 g (50th centile), and OFC of
34 cm (50th centile) and presented with clubfeet, congen-
ital bilateral hip dislocation, kyphoscoliosis, and marked
muscle hypotonia. He sustained his first fracture at age
12 months during physical examination and since has
had multiple fractures after minor trauma. Clinical exami-
nation at age 9 years revealed mild dysmorphic features
with blue sclerae, low-set ears, small yellowish teeth, asym-
metrical skull, and prognathism. He was unable to sit,
stand, or walk and spoke only a few words. He had low
muscle mass, severe generalized joint hyperlaxity, severe
kyphoscoliosis, and pectus excavatum. His skin was loose,
hyperextensible, and thin with prominent vessels. He had
excessive wrinkling of the dorsum of hands and increased
palmoplantar creases on hands and feet, with tapering fin-
gers and broad distal phalanges. At 8 years, a longstanding
retinal detachment was detected because of the shrunken
appearance of his left eye; deep vitrectomy together with
silicone oil injection was performed. Six months later, he
needed a revisional surgery as a result of redetachment of
the retina. Ophthalmic examination revealed excavation
of both optic nerves in the absence of high intraocular
pressure in multiple examinations under anesthesia. At
9 years, he sustained a cerebral hemorrhage after a head
trauma, for which a craniotomy was performed. His post-
operative scar had an atrophic aspect. Echocardiography
and evoked auditory brainstem response (EABR) were
normal. No radiographs were available.
Individual P4 is the 2-year-old sister of P3. She resides in
an institution for disabled children. Although a detailed
clinical description on her is not available, it is known
that she presents the same phenotype as her brother and
a blood sample was obtained. Individual P5 (Figures
2M–2P) is a 20-month-old girl, first and only child of
parents from Iranian descent, who are not knowingly
consanguineous but originate from the same village in
northwestern Iran. She was born after an uneventful preg-
nancy and delivery at 40 weeks, with a birth length of
47 cm (25th centile), weight of 2,750 g (10th centile), and
OFC of 33 cm (25th centile). She showed congenital bilat-
eral hip dislocation and clubfeet. At 4 months of age, she
sustained spontaneous bilateral fractures of the femur,
and X-rays at the time also revealed an old fracture of the
forearm. Subsequently, another fracture of the forearm
and rib fractures occurred after minor trauma. Clinical ex-
amination at 20 months showed a child with low muscle
mass and mild progeroid appearance. Her height was
65 cm (<3rd centile), weight 4,700 g (<3rd centile), and
OFC 45 cm (3rd centile). She was unable to hold her
head, sit, or stand and had not started to say any words.
She had mild dysmorphic features, as illustrated in Figures
2M and 2N. She displayed hyperlaxity of all joints, espe-
cially of fingers and wrists. Severe pectus excavatum was013
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Figure 3. Identification and Analysis of B3GALT6 Mutations and Their Effect on B3GALT6 Expression
(A) Pedigrees of families 1–3. Circles indicate females, squares indicate males. Symbols filled in black indicate affected family members
with proven homozygous or compound heterozygous B3GALT6 mutations. Partially filled symbols indicate proven heterozygous
carriers. Index persons are indicated by an arrow. Plus sign in the pedigree of family 1 indicates all members included in the homozy-
gosity mapping. Electropherograms are included when available.
(B) Representation of b3GalT6 protein structure with indication of the different domains and positions of the described mutations. Four
conserved motifs (I–IV) are shown in orange and a predicted N-linked glycosylation site is highlighted in pink.
(C) Clustal Omega protein sequence alignment showing part of the b3GalT6 galactosyltransferase domain including the substituted
amino acid residues. The protein sequence is highly conserved across vertebrates, invertebrates, and plants, and Asp207 and Gly217
residues are evolutionary highly conserved (with the latter localized within a consensus motif). Asterisk (*) indicates a single, fully
conserved residue; colon (:) indicates strong similar properties (>0.5 in the Gonnet PAM 250 matrix); and period (.) indicates weak
similar properties (%0.5 in the Gonnet PAM 250 matrix). Nucleotide numbering reflects cDNA numbering with þ1 corresponding to
the A of the ATG translation initiation codon in the reference sequence. At protein level, þ1 corresponds to the methionine translator
initiator.
(D) qRT-PCR analysis of B3GALT6 in P2, P3, P5, and three control individuals shows reduced B3GALT6 expression in affected individuals’
samples. Total RNAwas extracted with the RNeasy kit (QIAGEN), submitted to DNase Digestion (QIAGEN), and reverse-transcribed with
the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). All PCR reactions were carried out in duplicate. Relative expression was deter-
mined with the qbasePLUS software (Biogazelle, v.2.4) with HPRT1 and YWHAZ as reference genes. Data are expressed as mean 5
SEM; *p < 0.05, **p < 0.01 (Student’s t test).noted. Her skin was soft and doughy, with increased
palmar wrinkling. Radiographic features at age 2 years
3 months are shown in Figures 2U–2X. Sequence analysis
of B3GALT6 in P3 and P4 revealed a 22 bp deletion leadingThe Amto a frameshift and the introduction of a premature termi-
nation codon (c.323_344del [p.Ala108Glyfs*163]) in com-
pound heterozygosity with the c.619G>C (p.Asp207His)
mutation. In P5 a homozygous missense mutationerican Journal of Human Genetics 92, 935–945, June 6, 2013 939
(c.649G>A) resulting in a glycine-to-serine substitution
(p.Gly217Ser) was identified. All mutations segregated as
expected and were located within the predicted catalytic
galactosyltransferase domain of b3GalT6 (Figure 3B). The
Gly217 residue is also highly conserved among species
(Figure 3C), and its substitution is predicted to have a dele-
terious effect on protein function (Table S2). Both substitu-
tions were absent in 212 alleles of 106 healthy control
individuals and were not described in the 1000 Genomes
Project and the NHLBI Exome Sequencing Project (ESP)
Exome Variant Server (release ESP6500).
We combined several approaches to assess the functional
consequences of B3GALT6 mutations on b3GalT6 expres-
sion and activity, GAG synthesis rate, and CS/DS and HS
assembly by using dermal fibroblasts from individuals P2,
P3, and P5 and three unrelated healthy controls.
Quantitative RT-PCR (qRT-PCR) experiments revealed
significantly reduced B3GALT6 expression in samples
from affected individuals compared to healthy controls
(Figure 3D). We next analyzed the effect of the mutations
at b3GalT6 protein level and subcellular localization
by immunofluorescence microscopy by using anti-
b3GalT6 purified MaxPab mouse polyclonal antibody
(H00126792-B01P, Abnova) and anti-GOLPH4 rabbit
polyclonal antibody (ab28049, Abcam) (Figure S2). In con-
trol fibroblasts, b3GalT6 localized to the same subcellular
compartment as did GOLPH4, a Golgi-resident protein,
confirming previous reports that b3GalT6 is associated
with the cis Golgi compartment.11 No apparent modifica-
tion in the subcellular localization of the protein was
observed in affected individuals. However, in fibroblasts
of affected individuals, a decrease in b3GalT6 protein level
was noticed, as suggested by a reduced staining for
b3GalT6 compared to GOLPH4. Together with the reduced
transcript level, these data suggest that b3GalT6 is less
expressed and/or degraded and that mutations are associ-
ated with reduced protein level, in particular in individuals
P2 and P3.
To assess the functional consequences of B3GALT6
mutations on PG-GAG formation, we first analyzed the
capacity of control and of P2, P3, and P5 fibroblasts to
prime GAG synthesis on the exogenous xyloside 4-methyl-
umbelliferyl-b-D-xylopyranoside (4-MUX, Sigma-Aldrich).
The rate of GAG synthesis was evaluated by [35SO4]-incor-
poration in cultured cells as a function of xyloside concen-
tration, as previously described.24 Figure 4A shows a strong
decrease in the ability of individuals P2 and P5 to prime
GAG synthesis compared to the concentration-dependent
increase in GAG production in control fibroblasts. In P2
and P5 fibroblasts, GAG synthesis could be detected only
at the highest xyloside concentration (10 mM) and reached
55% and 35% that of control fibroblasts, respectively. P3
exhibited a complete lack of priming activity, indicating
a profound functional defect in terms of GAG synthesis.
In agreement, no detectable in vitro b3GalT6 activity
toward the model substrate Gal-Xyl-O-methoxynaphthyle
could be found in P3 fibroblasts, whereas the activity940 The American Journal of Human Genetics 92, 935–945, June 6, 2reached about 10 pmol.min1.mg protein1 in control
fibroblasts (not shown). Next, we examined the synthesis
and glycanation of the small CS/DS-PG decorin secreted
in affected and control dermal fibroblast cultures by immu-
noblotting by using an anti-human decorin antibody
(Clone 115402, R&D Systems). We observed disturbed pro-
cessing of decorin in conditioned medium from P3 and P5
fibroblast cultures compared to controls (Figure 4B). In
control samples, a single, broad band around 75 kDa corre-
sponding to the GAG-substituted decorin was detected. In
P3 and P5 samples, the glycanation of decorin was strongly
affected as illustrated by the almost complete loss of GAG
substitution in P3 and the presence of a second ~50 kDa
band, which was absent in control samples (Figure 4B).
Chondroitinase (CSase) ABC digestion showed that this
~50 kDa band corresponds to the unglycanated decorin
core protein (Figure S3). Moreover, after CSase ABC diges-
tion, the observed amount of the decorin core protein
was significantly lower in the samples from affected indi-
viduals as compared to controls. This decrease was more
pronounced in P3 than in P5. Concordantly, qRT-PCR
showed severely reduced DCN expression in fibroblast cul-
tures from affected individuals, compared to controls
(Figure 4C). In P3, decreased mRNA levels were also
observed for HSPG2, encoding perlecan, and LUM, encod-
ing lumican. In addition, XYLT2 and B4GALT7 expression
were also slightly reduced (Figure 4C). To assess whether
B3GALT6 mutations affect HS synthesis as well, we per-
formed immunofluorescence analysis of control and
affected dermal fibroblasts by using 10E4 anti-HS mono-
clonal antibodies, which are commonly used to detect
HS chains of cell PGs.25 Results showed a clear pericellular
staining of the HS epitope in control fibroblasts in contrast
to a reduced staining intensity in fibroblasts from P2 and
P5 and virtually no staining in fibroblasts from P3
(Figure 4D). These data strongly corroborate the idea that
B3GALT6 mutations partially affect HS synthesis in P2
and P5 and result in a virtual loss of HS in P3. Taken
together, our data suggest that the B3GALT6 mutations
affect the formation of the linkage region of GAG chains
of PGs leading to a defect in both CS/DS and HS-type chain
synthesis. The most severe defect was observed in fibro-
blasts of P3, carrying a compound heterozygous deletion
and an Asp-to-His substitution at position 207, leading to
reduced B3GALT6 expression, absence of detectable
b3GalT6 activity, and a virtual loss of CS/DS and HS syn-
thesis, whereas fibroblasts from P2 and P5 showed a partial
deficiency with reduced b3GalT6 activity, decreased level
of GAG synthesis, impaired HS synthesis, and partially
CS/DS-substituted decorin.
b3GalT6 belongs to the b1,3-galactosyltransferase fam-
ily, which exhibits a broad expression in adult human tis-
sues (Figure S4A and Cole et al.26 and Bai et al.11), in line
with the multisystemic character of the disorder described
in this study. B3GALT6 is highly conserved among
vertebrates, invertebrates, and plants (R. Oriol, S.F.-G.,
unpublished) and orthologs have been characterized in013
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Figure 4. Effect of B3GALT6 Mutations on b3GalT6 Activity and CS/DS and HS GAG Synthesis
(A) B3GALT6 mutations affect priming of GAG synthesis. GAG synthesis rate was evaluated in cultured fibroblasts from affected indi-
viduals and control by radiolabeled sulfate incorporation from the exogenous xyloside 4-methylumbelliferyl-b-D-xylopyranoside
(4-MUX, Sigma-Aldrich) as exogenous substrate as a function of time and concentration.24 Data are expressed as mean 5 SEM; *p <
0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
(B) Glycanation of decorin core protein is decreased in P2 and P5 fibroblast cultures compared to controls. Concentrated serum-free
conditioned medium was collected at day 7, subjected to SDS-PAGE (4%–12% Bis-Tris gel, Life Technologies) and blotting, and immu-
nolabeled with anti-human decorin antibody (Clone 115402, R&D Systems). The Precision Plus Protein All Blue Standard (Bio-Rad Lab-
oratories) was used as molecular mass marker. Control samples show a broad band of decorin-PG around ~75 kDa. In samples from
affected individuals, this decorin-PG band is decreased in intensity, and a second band (~50 kDa) is observed, corresponding to the
decorin core protein devoid of its CS/DS chain. In P3 a third, low-molecular band (~32 kDa), possibly a degradation product, is seen.
(C) Confocal immunofluorescence microscopy of HS with 10E4 anti-HS monoclonal antibodies25 shows a clear pericellular staining of
HS epitope in control human fibroblasts, in contrast to a reduced staining intensity for P2 and P5 and virtually no staining for P3 fibro-
blasts.
(D) qRT-PCR analysis shows a strong reduction ofDCN expression in all affected persons. A decreased expression of HSPG2 and LUMwas
observed in P3, whereas slight changes are noted forXYLT2 and B4GALT7 in some affected indivuals compared to controls. Experiments
were performed in duplicate as described in Figure 3D. Data are expressed as mean5 SEM; *p < 0.05, **p< 0.01, ***p < 0.001 (Student’s
t test).
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Figure 5. Effect of b3GalT6 Deficiency on Wound Closure and
Collagen Fibril and Elastin Ultrastructure
(A) Transmission electron microscopy shows a disturbed collagen
organization and ECM architecture. A skin biopsy was taken from
the upper anterior thigh of P5, fixed with 3% (w/v) glutaraldehyde
in phosphate buffer (pH 7.4), and analyzed with a Zeiss EM900
equipped with a 1K SlowScan CCD camera (Tro¨ndle). The observa-
tions were compared with control samples available from the skin
biopsy bank of the EM-Lab at Dermatology, University Clinic
Heidelberg. Collagen fibrils are loosely packed, with varying fibril
diameters and occasional fibrils with very irregular contours
(arrowhead).
(B) Quantitative analysis of in vitro wound closure in dermal fibro-
blasts from b3GalT6-deficient persons shows a delayed wound
closure for P2 and P3. Confluent cultures from control, P2, P3,
and P5 were subjected to a wound healing assay. Wound closure
was monitored 20 and 40 hr after wounding and recorded as num-
ber of migrated cells in the denuded area. Data are expressed as
mean5 SEM; *p < 0.05 (Student’s t test).Drosophila melanogaster27 and Caenorhabditis elegans.28 The
strong conservation of this gene among species is consis-
tent with the key role of b3GalT6 in GAG synthesis and
in the control of growth and pattern formation of tissues
during development. Interestingly, analysis of the expres-
sion profile of b3galt6 in zebrafish embryos by whole-
mount in situ hybridization showed high level of expres-
sion in brain, retina, pharyngeal arches, and notochord
epithelium, corresponding to tissues that are affected in
the deficient persons (Figure S4B). The observation of
high b3GalT6 expression in brain at early stages of zebra-
fish development, together with the presence of intellec-
tual disability in the b3GalT6-deficient individuals, points
to an important role of this enzyme in neurogenesis.
Indeed, GAG side chains of PGs are increasingly recog-
nized for their critical function in axon guidance and brain
development.29942 The American Journal of Human Genetics 92, 935–945, June 6, 2b3GalT6 catalyzes the addition of the second galactose
residue of the tetrasaccharide linkage of GAG chains, a
key step in the initiation of GAG synthesis (Figure 1).
Completion of the linker region is prerequisite to the poly-
merization of both CS/DS and heparin/HS-GAG chains,
which are covalently attached to PG core proteins, giving
rise to an array of PGs. Our studies provide strong evidence
that loss of function of b3GalT6 drastically affects GAG
synthesis and assembly. Decorin and biglycan are mem-
bers of the small leucine-rich PG (SLRP) family, which
are important constituents of the interstitial ECM. Decorin
is substituted by one GAG chain, mainly of the DS sub-
type. It plays an important role in the regulation of
collagen fibrillogenesis and is essential in maintaining
the structural and functional integrity of connective tis-
sues. Indeed, Dcn-null mice show severe abnormalities in
dermal collagen fiber size and shape and exhibit reduced
tensile strength and skin fragility.30 By transmission
electron microscopy on a skin biopsy of P5, we show
that b3GalT6 deficiency results in abnormal dermal
collagen fibril architecture characterized by loosely packed
collagen fibrils of variable size and shape, suggesting
that collagen fibrillogenesis is perturbed in this person
(Figure 5A). The decorin GAG chain also binds to tenas-
cin-X, another ECM protein involved in regulation of
collagen fibril architecture.31 Symptoms observed in
b3GalT6-deficient EDS persons are reminiscent of those
observed in tenascin-X-deficient individuals.32,33 The
combination of progressive contractures with striking
distal joint hypermobility and muscle hypotonia is also
reminiscent of the collagen VI-deficient Bethlem myop-
athy (MIM 158810) and Ullrich congenital muscular dys-
trophy (MIM 254090).34 Type VI collagen is present in
most tissues and is enriched close to cells and around base-
ment membranes. It interacts with a broad range of mole-
cules in vitro, including basement membrane components
like perlecan and ECM molecules like collagens type I, II,
and V, decorin, and biglycan.35–39 Together, these observa-
tions suggest that aberrant CS/DS substitution of SLRPs
such as decorin and the resulting defects in collagen supra-
molecular organization (Figure 5A) are responsible for
several of the clinical features observed in the b3GalT6-
deficient persons.
As shown in dermal fibroblasts from b3GalT6-deficient
persons, B3GALT6 mutations also produced deleterious
effects on HS synthesis, possibly contributing to some
phenotypic aspects of the disease, such as defective
wound closure. Indeed, it has been reported that cell sur-
face HS-PG of the syndecan family and the secreted
matrix HS-PG perlecan modulate wound repair in vivo
in a HS-dependent manner.40–42 Because affected individ-
uals described in this study suffer from impaired wound
repair, we employed an in vitro wound healing assay to
test whether B3GALT6 mutations can be linked to this
aspect of the phenotype. Compared with control cells,
no difference in wound closure was observed in P5. In
contrast, in fibroblasts of P2, wound closure was decreased013
by about 35% and 40% at 20 and 40 hr time periods,
respectively. The delay in wound closure was the most
dramatic for P3 (by about 65% and 75% at 20 and 40 hr
time period, respectively), in agreement with the severe
defect in GAG synthesis that was observed for this person
(Figures 5B and S5). These data confirm a role for GAGs in
the wound repair process and point to altered GAG
function as a possible cause of the delayed wound repair
phenotype in the most severely affected b3GalT6-
deficient individuals.
The clinical features of the b3GalT6 deficiency pheno-
type show significant overlap with those of several
recessive EDS variants (Table S3). The most significant
similarities exist with the musculocontractural and proge-
roid forms of EDS, conditions that are caused by defects in
enzymes that are also involved in GAG synthesis. Distinc-
tive features for b3GalT6-deficient EDS include the progres-
sive nature of the joint contractures, the severe bone
fragility with multiple fractures and spondyloepimetaphy-
seal dysplasia, and the presence of intellectual disability.
Clinical overlap also exists with other EDS variants that
fall within the EDS type VI spectrum, including EDS type
VIA (PLOD1 [MIM 153454]), spondylocheirodysplastic
EDS (MIM 612350, SLC39A13 [MIM 608735]), and
FKBP14-deficient EDS (MIM 614557, FKBP14 [MIM
614505]). A normal urinary LP/HP ratio allows distinction
of b3GalT6-deficient EDS from EDS VIA and spondylo-
cheirodysplastic EDS. The combination of increased
palmar wrinkling, progeroid appearance, osteoporosis,
and intellectual disability is also reminiscent of recessive
cutis laxa variants such as wrinkly skin syndrome (MIM
278250, ATP6V0A2 [MIM 611716]), geroderma osteodys-
plasticum (MIM 231070, GORAB [MIM 607983]), and De
Barsy syndrome (MIM 614438, PYCR1 [MIM 179035])
(Table S3). Interestingly, the skeletal abnormalities
observed in the b3GalT6-deficient EDS persons are highly
reminiscent of spondyloepimetaphyseal dysplasia with
joint laxity (SEMD-JL) type 1 (MIM 271640), a rare
autosomal-recessive skeletal dysplasia first described by
Beighton and Kozlowski,43,44 for which the genetic basis
has not yet been established. These observations suggest
that b3GalT6-deficient EDS and SEMD-JL are allelic
conditions.
In summary, we have shown that mutations in
B3GALT6, encoding a key enzyme in the formation of
the linkage region of the GAG chains of PGs, are respon-
sible for a unique combination of severe generalized
symptoms recapitulating Ehlers-Danlos syndrome and
characterized by connective tissue fragility, early-onset
bone fractures, spondyloepimethaphyseal dysplasia, and
intellectual disability. The key role of b3GalT6 in an early
step of GAG synthesis and the vital biological functions
of PG macromolecules, which range from mechanical
support to a variety of extra- and intracellular processes,
sustain the idea that mutations in B3GALT6 underlie a
multisystemic disorder that results from disturbances of
many physiological processes, including embryonic andThe Ampostnatal development, maintenance of ECM architecture,
and tissue repair.Supplemental Data
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